Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China - The Lancet
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy...
Iza-bren significantly improved the ORR compared with chemotherapy in individuals with heavily pretreated recurrent or m...
www.thelancet.com
Updated Estimates of Patients With Oropharyngeal Cancer in the US
Updated Estimates of Patients With Oropharyngeal Cancer in the US
This cross-sectional study examines the most recent epidemiologic estimates of oropharyngeal cancer in the US and prov...
jamanetwork.com
✅European Commission backs perioperative pembrolizumab for resectable PDL1 CPS+ locally advanced HNSCC
@OncoAlert @brunolarvol
@myESMO
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China - The Lancet
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy...
Iza-bren significantly improved the ORR compared with chemotherapy in individuals with heavily pretreated recurrent or m...
www.thelancet.com
Updated Estimates of Patients With Oropharyngeal Cancer in the US
Updated Estimates of Patients With Oropharyngeal Cancer in the US
This cross-sectional study examines the most recent epidemiologic estimates of oropharyngeal cancer in the US and prov...
jamanetwork.com
✅European Commission backs perioperative pembrolizumab for resectable PDL1 CPS+ locally advanced HNSCC
@OncoAlert @brunolarvol
@myESMO
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China - The Lancet
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy...
Iza-bren significantly improved the ORR compared with chemotherapy in individuals with heavily pretreated recurrent or m...
www.thelancet.com
Updated Estimates of Patients With Oropharyngeal Cancer in the US
Updated Estimates of Patients With Oropharyngeal Cancer in the US
This cross-sectional study examines the most recent epidemiologic estimates of oropharyngeal cancer in the US and prov...
jamanetwork.com
✅European Commission backs perioperative pembrolizumab for resectable PDL1 CPS+ locally advanced HNSCC
@OncoAlert @brunolarvol
@myESMO
TTCC en cifras
Entidades Colaboradoras
